News
Samsung introduces ‘revolutionary’ women’s health ultrasound
The system would provide clinicians with a suite of AI tools and applications to advance the diagnostic experience
Boston Imaging, the US headquarters of Samsung’s digital radiography and ultrasound business, has introduced a premium women’s health ultrasound to “free” healthcare professionals from repetitive tasks.
The HERA W10 Elite is the premier model of the HERA platform for obstetrics and gynaecology that aims to provide clinicians with a suite of AI tools and applications to advance the diagnostic experience.
The technology, the company says, could assist healthcare professionals in receiving greater insight in diagnosis with its “intuitive” visualisations, analytic features and fast operation.
In addition, the MV-Flow™ 3D function would help the system deliver “exceptional image clarity and colour sensitivity”, helping clinicians detect tiny structures in images without the need for excessive manipulation.
“Women’s health is a fast-growing field that requires state-of-the-art equipment for patient care,” said Tracy Bury, women’s health ultrasound business leader at Boston Imaging.
“The HERA W10 Elite will bring visionary change to obstetrics and gynaecology with sophisticated image processing and an ergonomic-friendly design.”
The system has been updated from its predecessor, with increased display area that shows the intensity of blood flow and allows the visualisation of the foetal heart and brain starting at eight weeks.
The product is also equipped with AI features, such as:
- HeartAssist™: to provide measurement results and classify an ultrasound image into measurement views required for foetal heart diagnosis
- ViewAssist™: to classify ultrasound images, annotate the structures and simplify the workflow
- BiometryAssist™: to enable clinicians to measure foetal growth parameters
Some hardware and software features for the system are pending clearance from the US Food and Drug Administration and are not yet available in the US.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Hormonal health3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Diagnosis2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






